Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Drevets

Showing results (21-30 of 337) with videos related to

Pageof 34
Sort By:
The Journal of the Kansas Medical Society|May 1, 1975
Therapeutic usefulness. 5-Fluorocytosine--a new anti-fungal agentC C Drevets, L M Hummer
Biological Psychiatry|January 16, 2010
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trialWayne C Drevets, Maura L Furey
Neurobiology of Disease|June 14, 2012
Neuroreceptor imaging in depressionJonathan B Savitz, Wayne C Drevets
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 21, 2009
Neurocircuitry of mood disordersJoseph L Price, Wayne C Drevets
Archives of General Psychiatry|October 4, 2006
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trialMaura L Furey, Wayne C Drevets
Neuroscience|April 11, 2009
Imaging phenotypes of major depressive disorder: genetic correlatesJ B Savitz, W C Drevets
Trends in Cognitive Sciences|December 27, 2011
Neural circuits underlying the pathophysiology of mood disordersJoseph L Price, Wayne C Drevets
Biological Psychiatry|January 1, 1989
Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer typeW C Drevets, E H Rubin
Psychopharmacology|August 20, 2013
Neural correlates of free T3 alteration after catecholamine depletion in subjects with remitted major depressive disorder and in controlsPhilipp Homan, Wayne C Drevets, Gregor Hasler
Journal of Clinical Psychopharmacology|August 22, 2013
Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controlsPhilipp Homan, Wayne C Drevets, Gregor Hasler
Pageof 34

Showing results (21-30 of 337) with videos related to

Sort By:
Pageof 34
The Journal of the Kansas Medical Society|May 1, 1975
Therapeutic usefulness. 5-Fluorocytosine--a new anti-fungal agentC C Drevets, L M Hummer
Biological Psychiatry|January 16, 2010
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trialWayne C Drevets, Maura L Furey
Neurobiology of Disease|June 14, 2012
Neuroreceptor imaging in depressionJonathan B Savitz, Wayne C Drevets
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 21, 2009
Neurocircuitry of mood disordersJoseph L Price, Wayne C Drevets
Archives of General Psychiatry|October 4, 2006
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trialMaura L Furey, Wayne C Drevets
Neuroscience|April 11, 2009
Imaging phenotypes of major depressive disorder: genetic correlatesJ B Savitz, W C Drevets
Trends in Cognitive Sciences|December 27, 2011
Neural circuits underlying the pathophysiology of mood disordersJoseph L Price, Wayne C Drevets
Biological Psychiatry|January 1, 1989
Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer typeW C Drevets, E H Rubin
Psychopharmacology|August 20, 2013
Neural correlates of free T3 alteration after catecholamine depletion in subjects with remitted major depressive disorder and in controlsPhilipp Homan, Wayne C Drevets, Gregor Hasler
Journal of Clinical Psychopharmacology|August 22, 2013
Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controlsPhilipp Homan, Wayne C Drevets, Gregor Hasler
Pageof 34